Literature DB >> 7715060

Age-specific incidence of Alzheimer's disease in a community population.

L E Hebert1, P A Scherr, L A Beckett, M S Albert, D M Pilgrim, M J Chown, H H Funkenstein, D A Evans.   

Abstract

OBJECTIVE: To determine age-specific incidence rates of clinically diagnosed Alzheimer's disease.
DESIGN: Cohort, followed a mean of 4.3 years.
SETTING: East Boston, Mass. PARTICIPANTS: Of 2313 persons aged 65 years and older who were initially free of Alzheimer's disease, 1601 participated in the ascertainment of incident disease (80% of survivors), 409 declined participation, and 303 died before the end of the follow-up period. A stratified sample of 642 persons received detailed clinical evaluation. OUTCOME MEASURE: Diagnosis of new probable Alzheimer's disease through structured clinical evaluation including neurologic, neuropsychological, and psychiatric examination. Community incidence rates were computed by 5-year age groups, adjusted for gender, single year of age, length of follow-up interval, and sampling design.
RESULTS: The estimated annual incidence of Alzheimer's disease in the population was 0.6% (95% confidence interval [CI], 0.3% to 0.9%) for persons aged 65 to 69 years, 1.0% (95% CI, 0.6% to 1.4%) for persons aged 70 to 74 years, 2.0% (95% CI, 1.3% to 2.7%) for persons aged 75 to 79 years, 3.3% (95% CI, 2.2% to 4.4%) for persons aged 80 to 84 years, and 8.4% (95% CI, 3.7% to 13.1%) for persons aged 85 years and older.
CONCLUSIONS: The incidence of Alzheimer's disease is substantial and is approximately 14 times higher among persons older than 85 years compared with those between 65 and 69 years of age.

Entities:  

Mesh:

Year:  1995        PMID: 7715060

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  106 in total

1.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.

Authors:  C R Jack; R C Petersen; Y C Xu; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; S C Waring; E G Tangalos; E Kokmen
Journal:  Neurology       Date:  1999-04-22       Impact factor: 9.910

Review 2.  Hormonal influences on cognition and risk for Alzheimer's disease.

Authors:  Sarah C Janicki; Nicole Schupf
Journal:  Curr Neurol Neurosci Rep       Date:  2010-09       Impact factor: 5.081

3.  Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Reisa A Sperling; Paul S Aisen; Laurel A Beckett; David A Bennett; Suzanne Craft; Anne M Fagan; Takeshi Iwatsubo; Clifford R Jack; Jeffrey Kaye; Thomas J Montine; Denise C Park; Eric M Reiman; Christopher C Rowe; Eric Siemers; Yaakov Stern; Kristine Yaffe; Maria C Carrillo; Bill Thies; Marcelle Morrison-Bogorad; Molly V Wagster; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

4.  The contingency of contingent valuation. How much are people willing to pay against Alzheimer's disease?

Authors:  Sandra Nocera; Dario Bonato; Harry Telser
Journal:  Int J Health Care Finance Econ       Date:  2002-09

Review 5.  Challenges and opportunities for developing and implementing incentives to improve health-related behaviors in older adults.

Authors:  Eran Klein; Jason Karlawish
Journal:  J Am Geriatr Soc       Date:  2010-09       Impact factor: 5.562

6.  Polysomnographic and subjective sleep markers of mild cognitive impairment.

Authors:  Eva Hita-Yañez; Mercedes Atienza; Jose L Cantero
Journal:  Sleep       Date:  2013-09-01       Impact factor: 5.849

7.  Gonadal hormones modulate the potency of the disruptive effects of donepezil in male rats responding under a nonspatial operant learning and performance task.

Authors:  Stuart T Leonard; John K Hearn; Andrew D Catling; Peter J Winsauer
Journal:  Behav Pharmacol       Date:  2010-03       Impact factor: 2.293

Review 8.  Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.

Authors:  Greg L Plosker; Katherine A Lyseng-Williamson
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

9.  Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-β.

Authors:  Tanusree Sen; Pampa Saha; Nilkantha Sen
Journal:  Sci Signal       Date:  2018-03-20       Impact factor: 8.192

10.  Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline.

Authors:  M C Morris; D A Evans; J L Bienias; P A Scherr; C C Tangney; L E Hebert; D A Bennett; R S Wilson; N Aggarwal
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.